I-Mab and HI-Bio’s Felzartamab Earns Breakthrough Therapy Designation from US FDA
China-based I-Mab (NASDAQ: IMAB) and its US partner HI-Bio have announced that they have received...
Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances
Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter...
Organon Reports Q3 2023 Financials with Mixed Results, Notable Decline in Women’s Health Sales
US-based Organon (NYSE: OGN) has released its financial results for the third quarter of 2023,...
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third...
AstraZeneca Partners with Cellectis for Next-Generation Cell and Gene Therapies
UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced a strategic partnership with Cellectis (EPA:...
Daiichi Sankyo Reports 19.5% YOY Revenue Growth in First Half of Fiscal 2023
Japan’s Daiichi Sankyo (TYO: 4568) reported a robust 19.5% year-on-year (YOY) increase in revenue for...
EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting
Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its...
GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third...
We-Linking Secures Angel Financing for Implantable Brain Computer Interface Development
Shenzhen-based company We-Linking, a specialist in implantable brain computer interfaces (BCI), has reportedly raised tens...
Chongqing Precision Biotechnology’s PCAR-19B Receives CDE Nod for Breakthrough Therapy Designation
The China’s Center for Drug Evaluation (CDE) website has indicated that Chongqing Precision Biotechnology Co.,...
Astellas Pharma Inc. Reports Moderate Revenue Growth in H1 Fiscal 2023 Financials
Japan-based Astellas Pharma Inc., (TYO: 4503) has released its financial results for the first half...
Sichuan Kelun-Biotech’s SKB264 Receives Priority Review Status for TNBC Treatment in China
The China’s Center for Drug Evaluation (CDE) website has indicated that Sichuan Kelun-Biotech Biopharmaceutical Co.,...
Hinova Pharmaceuticals’ HP518 Receives NMPA Approval for mCRPC Clinical Trial
China-based biopharmaceutical company Hinova Pharmaceuticals (SHA: 688302) has announced that it has received clinical trial...
Sino Biopharmaceutical’s TQG3902 Injection Receives NMPA Approval for Septic Shock Clinical Trial
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biotech company based in China, has announced that...
Sirnaomics’ STP705 Demonstrates Positive Results in Phase I Focal Fat Reduction Study
Sirnaomics Ltd (HKG: 2257) has announced positive safety and efficacy results from a Phase I...
3SBio Inc. and CStone Pharmaceuticals Enter Strategic Partnership for Nofazinlimab
China-based 3SBio Inc., (HKG: 1530) has announced a strategic partnership and exclusive licensing agreement with...
Resolian Expands Global Reach with Acquisition of China-Based Denali Medpharma
US-based bioanalytical contract research organization (CRO) Resolian has announced the acquisition of China-based CRO Denali...
Hainan Poly Pharm Receives FDA Approval for PL002 in Primary Liver Cancer Surgery
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced that it has received clinical...
Changchun BCHT Biotechnology Receives NMPA Approval for Anti-Tetanus Monoclonal Antibody Injection
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced that it has received clinical...
Shenzhen Chipscreen Biosciences Gets NMPA Approval for Phase I Study of CS32582 in Psoriasis
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced that it...